The Data Management Core will provide the following services to this Program Project: (1) register patients on protocol, enter basic clinical data into the data base, assess response and subsequent clinical status of patients, and (2) extend the current clinical data base to include data from the laboratory projects and assure the functionality and integrity of the data base. For purposes of patient registration on protocol and follow-up of subsequent response and survival, we will use established routines in the Leukemia Department at MDACC. These are overseen by experienced personnel and have been the basis for many publications. The existing leukemia data base contains pre-treatment, response, and survival data on > 1,000 patients with AML and has supported numerous publications. This data base resides on a VAX computer and is accessed via the VA Filemanager software package. Data from Blood and Marrow Transplant patients (Project 4) are transferred to the Leukemia Data Base as are data from the laboratory based research Projects 1-3. Laboratory data are assembled in an Access Data Base, which serves as a portal to the Leukemia data base. Fields for all ongoing projects have been developed. Data base dictionaries are in place, as are stringent QC and security measures. Routine audits are performed to insure that the database matches the primary research records in the laboratory. Files are transferred from Core D1 to Core D2 for biostatistical analysis. Dr. Stephen Condit, Systems Analyst from the Fred Hutchinson Cancer Research Center has reviewed the database and has agreed to serve as Consultant.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA055164-10A1
Application #
6479197
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
1992-06-01
Project End
2005-06-30
Budget Start
Budget End
Support Year
10
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Ruvolo, Peter P; Ruvolo, Vivian R; Burks, Jared K et al. (2018) Role of MSC-derived galectin 3 in the AML microenvironment. Biochim Biophys Acta Mol Cell Res 1865:959-969
Ngankeu, Apollinaire; Ranganathan, Parvathi; Havelange, Violaine et al. (2018) Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget 9:4354-4365
Le, Phuong M; Andreeff, Michael; Battula, Venkata Lokesh (2018) Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis. Haematologica :
Jiang, Xuejie; Mak, Po Yee; Mu, Hong et al. (2018) Disruption of Wnt/?-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia. Clin Cancer Res 24:2417-2429
Ishizawa, Jo; Nakamaru, Kenji; Seki, Takahiko et al. (2018) Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res 78:2721-2731
Sekihara, Kazumasa; Saitoh, Kaori; Han, Lina et al. (2017) Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1. Oncotarget 8:34552-34564
Carter, Bing Z; Mak, Po Yee; Wang, Xiangmeng et al. (2017) Focal Adhesion Kinase as a Potential Target in AML and MDS. Mol Cancer Ther 16:1133-1144
Zeng, Zhihong; Liu, Wenbin; Tsao, Twee et al. (2017) High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia. Haematologica 102:1537-1548
Pan, Rongqing; Ruvolo, Vivian; Mu, Hong et al. (2017) Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy. Cancer Cell 32:748-760.e6
Jacamo, Rodrigo; Davis, R Eric; Ling, Xiaoyang et al. (2017) Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia. Oncotarget 8:83354-83369

Showing the most recent 10 out of 422 publications